Exicure Stock Forecast, Price & News

Exicure (NASDAQ:XCUR) Frequently Asked Questions

Is Exicure a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exicure stock.
View analyst ratings for Exicure or view top-rated stocks.

How has Exicure's stock been impacted by COVID-19?

Exicure's stock was trading at $1.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XCUR stock has decreased by 72.6% and is now trading at $0.4553.
View which stocks have been most impacted by COVID-19.

When is Exicure's next earnings date?

Exicure is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Exicure.

How were Exicure's earnings last quarter?

Exicure, Inc. (NASDAQ:XCUR) released its quarterly earnings results on Friday, November, 19th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.18. The company earned ($3.68) million during the quarter, compared to the consensus estimate of $0.80 million. Exicure had a negative net margin of 1,318.75% and a negative trailing twelve-month return on equity of 87.09%.
View Exicure's earnings history.

What price target have analysts set for XCUR?

3 brokerages have issued 1 year price targets for Exicure's shares. Their forecasts range from $2.25 to $6.00. On average, they expect Exicure's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 943.3% from the stock's current price.
View analysts' price targets for Exicure or view top-rated stocks among Wall Street analysts.

Who are Exicure's key executives?

Exicure's management team includes the following people:

• David A. Giljohann, Chief Executive Officer, Secretary & Director
• Matthias G. Schroff, Chief Operating Officer
• Brian C. Bock, Chief Financial Officer
• Emil M. deGoma, Vice President-Clinical Development
• Douglas E. Feltner, Chief Medical Officer

Who are some of Exicure's key competitors?

Some companies that are related to Exicure include Millendo Therapeutics (MLND), Decibel Therapeutics (DBTX), Viracta Therapeutics (VIRX), ObsEva (OBSV), Sol-Gel Technologies (SLGL), SCYNEXIS (SCYX), MediciNova (MNOV), Esperion Therapeutics (ESPR), Reneo Pharmaceuticals (RPHM), BriaCell Therapeutics (BCTX), Corvus Pharmaceuticals (CRVS), Satsuma Pharmaceuticals (STSA), iBio (IBIO), NexImmune (NEXI) and Aptinyx (APTX).
View all of XCUR's competitors.

What is Exicure's stock symbol?

Exicure trades on the NASDAQ under the ticker symbol "XCUR."

Who are Exicure's major shareholders?

Exicure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Tybourne Capital Management HK Ltd. (8.31%), Prosight Management LP (5.82%), Geode Capital Management LLC (0.76%), Millennium Management LLC (0.68%), BlackRock Inc. (0.58%) and Dimensional Fund Advisors LP (0.17%). Company insiders that own Exicure stock include Aurasense Llc and Elias D Papadimas.
View institutional ownership trends for Exicure.

Which institutional investors are selling Exicure stock?

XCUR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Geode Capital Management LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., and Tybourne Capital Management HK Ltd..
View insider buying and selling activity for Exicure or view top insider-selling stocks.

Which institutional investors are buying Exicure stock?

XCUR stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, BlackRock Inc., HighTower Advisors LLC, UBS Group AG, and Raymond James & Associates.
View insider buying and selling activity for Exicure or or view top insider-buying stocks.

How do I buy shares of Exicure?

Shares of XCUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exicure's stock price today?

One share of XCUR stock can currently be purchased for approximately $0.46.

How much money does Exicure make?

Exicure has a market capitalization of $40.12 million and generates $16.61 million in revenue each year. The company earns $-24.67 million in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Exicure have?

Exicure employs 63 workers across the globe.

What is Exicure's official website?

The official website for Exicure is www.exicuretx.com.

Where are Exicure's headquarters?

Exicure is headquartered at 2430 N. Halsted St., Chicago IL, 60614.

How can I contact Exicure?

Exicure's mailing address is 2430 N. Halsted St., Chicago IL, 60614. The company can be reached via phone at (847) 673-1700 or via email at [email protected].